@article{322d58d7d27b4fe8a5bd1ee0b9137ac9,
title = "In Vitro Antibiofilm Activity of Hydrogen Peroxide-Generating Electrochemical Bandage against Yeast Biofilms",
abstract = "Wound infections are caused by bacteria and/or fungi. The presence of fungal biofilms in wound beds presents a unique challenge, as fungal biofilms may be difficult to eradicate. The goal of this work was to assess the in vitro antibiofilm activity of an H2O2-producing electrochemical bandage (e-bandage) against 15 yeast isolates representing commonly encountered species. Time-dependent decreases in viable biofilm CFU counts of all isolates tested were observed, resulting in no visible colonies with 48 h of exposure by plate culture. Fluorescence microscopic analysis showed extensive cell membrane damage of biofilm cells after e-bandage treatment. Reductions in intracellular ATP levels of yeast biofilm cells were recorded post e-bandage treatment. These results suggest that exposure to H2O2-producing e-bandages reduces in vitro viable cell counts of yeast biofilms, making this a potential new topical treatment approach for fungal wound infections.",
keywords = "Candida, Electrochemical bandage, Hydrogen peroxide, Yeast biofilm",
author = "Raval, {Yash S.} and Abdelrhman Mohamed and Mandrekar, {Jayawant N.} and Cody Fisher and Greenwood-Quaintance, {Kerryl E.} and Haluk Beyenal and Robin Patel",
note = "Funding Information: This research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under grant number R01 AI091594. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Copyright {\textcopyright} 2022 American Society for Microbiology. All Rights Reserved. Address correspondence to Robin Patel, patel.robin@mayo.edu. The authors declare a conflict of interest. R.P. reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. R.P. is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, CARB-X, and Qvella; monies are paid to Mayo Clinic. Mayo Clinic and Dr. Patel have a relationship with Adaptive Phage Therapeutics. R.P. is also a consultant to Netflix. In addition, R.P. has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. R.P. receives an editor's stipend from IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. H.B. holds a patent (US20180207301A1), “Electrochemical reduction or prevention of infections,” which refers to the electrochemical scaffold described herein. Received 10 September 2021 Returned for modification 12 October 2021 Accepted 14 December 2021 Accepted manuscript posted online 20 December 2021 Published Publisher Copyright: {\textcopyright} 2022 American Society for Microbiology.",
year = "2022",
month = feb,
doi = "10.1128/aac.01792-21",
language = "English (US)",
volume = "66",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",
}